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Cannabis sativa has been known, used, and misused by mankind for centuries, and yet only over the
last twodecadeshas researchstemming from thechemical constituents specific to thisplant, thecan-
nabinoids, started to provide fundamental insights into animal physiology and pathology, resulting in
thedevelopment of new therapeutics. Thediscoveryof the endocannabinoid system, and its targeting
with two newpharmaceutical preparations nowon themarket in several countries, represent themost
recent example of how studies on medicinal plants and on the mechanism of their biological effects
can reveal, through a chain of breakthroughs, new systems of endogenous signals and physiological
phenomena that can become the source of novel strategies for unmet therapeutic challenges.Introduction
The cannabinoid CB1 receptor antagonist, rimonabant,
has beenmarketed since August 2006 in several EU coun-
tries under the commercial name of Acomplia as a phar-
macological aid to exercise and calorie-intake reduction
for the treatment of obesity and its metabolic complica-
tions, such as dyslipidemia and glucose intolerance [1].
About a year earlier, Sativex, a pharmaceutical prepara-
tion based on extracts of Cannabis sativa, and containing
the psychotropic cannabinoid D9-tetrahydrocannabinol
(THC) together with the nonpsychotropic cannabidiol (Fig-
ure 1) in an 1:1 ratio, was introduced in Canada for the
treatment of neuropathic pain associated with multiple
sclerosis [2]. These recent milestones of the exploitation
of the plant with perhaps the oldest history of medicinal
and recreational use by mankind are the result of four
decades of intensive research. This process started with
the identification and chemical synthesis of THC, the
controlled study of its pharmacological properties, and
the identification of its receptors in animal organisms
and of their endogenous ligands, the endocannabinoids
(Figure 1), and it continued with the progressive under-
standing of the physiological and pathological roles of
this newly discovered signaling system and the apprecia-
tion of the potential therapeutic use not only of THC and
endocannabinoids, but also of other plant cannabinoids.
Despite this impressive sequence of achievements,
whose aspects have been the subject of recent ‘‘histori-
cal’’ reviews [3–5], there is much more to the original
understanding of the THC mechanism of action than the
discovery of the endocannabinoid system. The purpose
of this article is not merely to highlight the past contribu-
tion of chemical biology to our current understanding of
endocannabinoid regulation and function, but, more
importantly, to discuss the several other discoveries thatChemistry & Bistemmed, and are still likely to originate in the future,
from the finding of cannabinoid receptors and their endog-
enous ligands.
From Plant Chemicals to Chemical Signals:
Are Endocannabinoids Just Like Endorphins?
Thanks to the chemical synthesis of enantiomerically pure
THC analogs (Figure 1), it became clear that the pharma-
cological actions of this compoundwere notmerely due to
its capability to alter membrane permeability in a nonspe-
cific way, but rather to the interaction with specific binding
sites. The same analogs, once chemically modified and
radiolabelled, served as a tool for the identification of
these ‘‘cannabinoid’’ receptors in the rat brain [6]. The
finding of the first cannabinoid receptor, the CB1, out of
a series of previously cloned orphan G protein-coupled
receptors (GPCRs), soon to be followed by the homology
cloning of the second type of cannabinoid receptors, the
CB2, marked the beginning of the discovery of the endog-
enous cannabinoid signaling system and prompted the
search for endogenous ligands, much in the same way
as the identification of receptors for another plant natural
product, morphine, had led to the identification of the
endorphins two decades earlier. This search, however,
might have lasted for several years had it not been guided
by a chemical concept, i.e., that, by homology to the highly
lipophilic THC, physiological cannabinoid receptor
ligands were to be looked for among endogenous lipids
rather than peptides like the endorphins. This idea was
also supported by the observation that CB1 receptors
exhibit relatively high homology with the GPCRs for an-
other family of lipid signals, the lysophosphatidic acids.
The identification of the fatty acid ethanolamide ananda-
mide (N-arachidonoylethanolamide) [7] and of its glycerol
ester analog, 2-arachidonoyl-glycerol (2-AG) [8, 9], asology 14, July 2007 ª2007 Elsevier Ltd All rights reserved 741
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ReviewFigure 1. Chemical Structures of the
Most-Studied Endocannabinoids, of
a Cannabinoid Receptor Antagonist, and
of Some Plant Cannabinoids
Chemical structures of (1) the two best-studied
endocannabinoids, anandamide and 2-arachi-
donoyl glycerol [7–9]; (2) the CB1 receptor
antagonist/inverse agonist rimonabant, now
on the market under the trade name Acomplia,
as a pharmacological aid for the therapy of
obesity and the metabolic syndrome [1]; (3)
the two major plant cannabinoids, the psycho-
tropic D9-THC and the nonpsychoactive
cannabidiol, which are also the major constitu-
ents, in a 1:1 ratio, of Sativex, currently mar-
keted in Canada against neuropathic pain in
patients with multiple sclerosis [2].endogenous agonists of CB1 andCB2 receptors (Figure 1),
and the subsequent finding of their metabolic pathways
and enzymes (see [10] for an updated review; see
Figure S1 in the Supplemental Data available with this
article online), provided the basis for the study of the
physiological and pathological role of this endogenous
signaling apparatus.
Beyond the similar history of their discoveries, the com-
monalities between opioid and cannabinoid receptors
have been known even before the discovery of the latter,
and they include similar inhibitory actions on nociception,
gastrointestinal and cardiovascular function, anxiety and
stress, and facilitatory actions on food intake and reward
in laboratory animals (see [11–13] for recent reviews; Ta-
ble S1). The coupling, via inhibitory Gi/o proteins, of these
two receptors to similar intracellular signaling pathways
[14] underlies, to some extent, these similarities, whereas
interactions between these pathways [13] probably ex-
plain why antagonists of each receptor type sometimes
counteract the pharmacological effects induced by the
stimulation of the other. However, one should not get
the impression that the endocannabinoid system is
a mere functional duplication of opioidergic signaling.
The emerging scenario, in fact, distinguishes between
the general strategies of endocannabinoid and endoge-
nous opioid signaling based on the fact that, unlike endor-
phins, anandamide and 2-AG are lipophilic compounds
produced from membrane phosphoglycerides via Ca2+-
sensitive biosynthetic pathways triggered on demand,
rather than being prestored in secretory vesicles. Hence,
because of their chemical nature, endocannabinoids do
not typically function like hormones, but they instead act
as local (autocrine or paracrine) mediators. This is clearly
the case with endocannabinoid action in the brain, where
the elevation of intracellular Ca2+ caused by postsynaptic
neuron depolarization or stimulation of postsynaptic neu-
rotransmitter receptors coupled to Ca2+ mobilization from
intracellular stores, or both, stimulates enzymes catalyz-
ing the biosynthesis of anandamide and, particularly, 2-
AG. These compounds are then released from the neuron
to activate presynaptic CB1 receptors that, in most cases
via inhibition of voltage-activated calcium channels, re-742 Chemistry & Biology 14, July 2007 ª2007 Elsevier Ltd All rigduce the release of both excitatory (e.g., glutamate) and
inhibitory (e.g., GABA) neurotransmitters, thereby produc-
ing various effects on neuronal synapses [15]. This ‘‘retro-
grade’’ mode for endocannabinoid action (Figure S1) has
been implicated in several physiopathological functions of
the brain, including the control of food intake, habit-form-
ing and mnemonic processes, neuronal plasticity, and ex-
citotoxicity. Since the biosynthetic precursors for endo-
cannabinoids seem to be ubiquitous in membranes, it is
the reciprocal pattern of expression of endocannabinoid
biosynthesising enzymes and cannabinoid receptors
that determines the specificity of endocannabinoid ac-
tion, whereas the localization of the degrading enzymes
sets its duration. Indeed, the sn-1-specific diacylglycerol
lipase (DAGL)-a catalyzing 2-AG release from diacylgly-
cerols [16] is expressed in postsynaptic dendritic
‘‘spines’’ that make synapses with axon terminals ex-
pressing CB1 receptors [17, 18]. This allows a lipophilic
molecule like 2-AG to reach its target in close proximity
to its site of biosynthesis. Also, one of the enzymes re-
sponsible for 2-AG degradation, the monoacylglycerol
lipase (MAGL), is located in presynaptic neurons, thus
allowing for the immediate inactivation of the endocanna-
binoid signal [19]. Elegant experiments established the
time and space frames for endocannabinoid retrograde
action [20, 21], which can distinguish between neigh-
boring CB1-expressing glutamate- and GABA-releasing
neurons as targets [22, 23]. The type and time coinci-
dence of Ca2+-mobilizing stimuli play a major role in deter-
mining the occurrence of retrograde signaling by endo-
cannabinoids [24, 25].
Experiments are being performed to extend this mode
of action also to CB2 receptors or to nonneuronal cells,
including lymphocytes, macrophages, andmicroglial cells
(for the control of the immune and inflammatory re-
sponses) [26, 27]; endothelial cells (for the control of
vascular tone and angiogenesis) [28]; adipocytes and
pancreatic b cells (for the control of adipokine and insulin
secretion) [29] or other endocrine cells [30]; and to repro-
ductive tissues [31, 32]. For example, the tight control
in time and space of endocannabinoid biosynthesis
and degradation within the framework of the chemicalhts reserved
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ReviewFigure 2. Schematic Representation of
the Binding Site of Fatty Acid Amide
Hydrolase
Schematic representation of the active site of
fatty acid amide hydrolase (FAAH), with
‘‘hydrophobic’’ and ‘‘polar head’’ pockets
(‘‘ACB’’ and ‘‘AC’’ channels, respectively) to
accommodate anandamide and other fatty
acid amides, as deduced from crystallographic
studies [39] and structure-activity relationship
studies carried out with several analogs of
FAAH inhibitors [43]. Note how the ‘‘AC’’ chan-
nel can theoretically accommodate bulkier
groups than ethanolamine. Arachidonoyl-
trifluoromethylketone (TFMK) and its analogs
[34] were used for the affinity chromatography
purification of FAAH [35], whereas methyl-
arachidonoyl-fluoro-phosphonate (MAFP) was
used to obtain crystals from a slightly modified
and purified form of FAAH [39]. Carbamate
inhibitors like URB597 (see also Table S2)
were suggested to enter the active site in
away opposite that of the fatty acid derivatives,
with the ester rather than the amide bond being
cleaved by the catalytic action of Ser241 [43].communication between the fertilized egg and cells of the
oviduct and uterus is crucial for the correct implantation
of the embryo [33]. Thus, although, like the endorphins,
they exert a homeostatic function, the endocannabinoids,
ultimately due to their chemical nature and peculiar bio-
synthetic pathways (and to the fact that constitutive CB1
receptors are muchmore widely distributed than originally
thought, whereas CB2 receptors appear to be upregulated
under several pathological conditions), play a local and yet
more general function, seemingly regarding all aspects of
animal health and disease (Table S1).
Faces and Facets of Endocannabinoid Metabolic
Pathways and Enzymes
The interplay between chemistry and biology played
a major role in the identification of the enzymes catalyzing
endocannabinoid synthesis and degradation. The fatty
acid amide hydrolase (FAAH), which catalyzes the hydro-
lysis of anandamide (and of other bioactive fatty acid
amides, see below) and 2-AG, was isolated after the
synthesis of inhibitors [34], which were then used for affin-
ity chromatography purification of the enzyme. This even-
tually led to the cloning of FAAH [35], now considered to
be a promising target for the development of new anxio-
lytic and analgesic drugs [36–38]. Also, the X-ray structure
of FAAH was obtained thanks to the fact that a ‘‘modified
version’’ of the purified enzyme yields good crystals only
when covalently bound to an irreversible active-site inhib-
itor [39]. As to the cloning of the DAGL-a and -b catalyzing
2-AG formation from diacylglycerols, this was achieved
by using a bioinformatic approach, i.e., starting from the
gene encoding a DAGL from Penicillium, and then ‘‘fish-
ing’’ for orthologs in the sequenced genomes of increas-
ingly complex animal organisms, ending with the human
genome [16].
FAAH is an unusual enzyme since, unlike most serine
hydrolases which employ a Ser-His-Asp triad, its catalyticChemistry & Biomechanism involves a Ser-Ser-Lys triad [40] (Figure 2).
This is consistent with mutagenesis and enzymological
studies indicating that Ser241 plays a critical role as
both acid and base in the hydrolytic cycle, whereas
Lys142 is the activator of Ser241 [41, 42]. Mutagenesis
studies also involve Ser217, a residue conserved in all
enzymes with an amidase signature sequence, in the cat-
alytic mechanism of FAAH. This residue may act as
a ‘‘bridge’’ that, through a proton shift, facilitates both
the nucleophile attack and the exit of the leaving group.
The FAAH crystal structure revealed the existence of an
acyl chain-binding (ACB) channel for entry of hydrophobic
substrates and a cytoplasmatic access (AC) channel for
hydrophilic compounds, i.e., water for substrate hydroly-
sis and hydrophilic breakdown products. This latter chan-
nel is also likely to accommodate the polar head of anan-
damide and other fatty acid amides [40, 43] (Figure 2).
Despite its atypical catalytic mechanism, FAAH is in-
hibited by most classical serine hydrolase inhibitors,
including trifluoromethyl ketones, fluorophosphonates,
carbamates, and a-ketoheterocycle compounds (Table
S2). The inhibitory mechanism of these compounds is
based on the presence in their structures of a strong
electrophile that engages the Ser241 nucleophile in either
a covalently reversible or irreversible manner. However,
the systematic evaluation of the selectivity of these FAAH
inhibitors against other Ser hydrolases is necessary to de-
lineate their therapeutic potential. A chemical proteomic
approach known as ‘‘activity-based protein profiling’’
(ABPP) has been used to assess the selectivity of several
FAAH inhibitors [44]. ABPP methods, by using active site-
directed chemical probes, allow for the screening of in-
hibitors against multiple enzymes in parallel, and conse-
quently for the detection of possible off-target enzymes
[45]. More recently, a multidimensional protein-identifica-
tion technology (MudPIT) was employed to identify the
major off-targets for several FAAH inhibitors [46]. Usinglogy 14, July 2007 ª2007 Elsevier Ltd All rights reserved 743
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(A) The three pathways proposed forN-arachidonoylphosphatidyl-ethanolamine conversion into anandamide as an alternative to the one represented
in Figure S1 [50–52]. Although speculative, it is possible that the multiplicity of the biosynthetic pathways of anandamide reflects to some extent its
capability to interact at a submicromolar concentration with several molecular targets [126], including, in addition to cannabinoid receptors, opposing
actions on TRPV1 (activation) and TRPM8 (inhibition) [127] channels (see Figure 5).
(B) Biosynthesis and degradation of 2-arachidonoylglycerol seen as a sequence of different signals acting on different targets at different times. Apart
from being converted, as discussed in the text, to arachidonic acid and to a COX-2 derivative with specific targets, 2-AG can be transformed into, and
produced from, 2-arachidonoyl-lysophosphatidic acid, which activates LPA receptors with relatively high homology with CB1 receptors [128].744 Chemistry & Biology 14, July 2007 ª2007 Elsevier Ltd All rights reserved
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known as URB-597 [36] and BMS-1 (but not SA-72
[47]), the carbamoyl tetrazole LY2077855, and the a-keto-
heterocycle OL-135 [37] act on off-targets [44–46]
(Table S2). Also, the recently developed irreversible inhib-
itors of DAGLs [48] are ideal candidates to be investigated
with proteomics-type strategies. These compounds,
known as O-3841 and O-3640, are fluorophosphonate
derivatives of oleic acid and are at least selective against
other proteins of the endocannabinoid system.
In view of the ‘‘only when and where needed’’ character
of their action, and of the increasing evidence that
endocannabinoids participate in several pathological
conditions [10], it can be foreseen that inhibitors of their
biosynthesis or catabolism will be used for the pharmaco-
logical treatment of disorders ranging from neuropathic
pain and psychiatric/neurological disorders to hyperten-
sion and obesity, possibly in a more selective way than
with cannabinoid receptor agonists (see [49] for a compre-
hensive review). However, two peculiar aspects of
endocannabinoid metabolic pathways should call for cau-
tion when it comes to their therapeutic exploitation (Fig-
ure 3): (1) the high degree of redundancy with which endo-
cannabinoids are made and/or degraded—this means
that, for example, inhibiting just one of the several path-
ways that have been suggested so far for anandamide
biosynthesis from N-arachidonoyl-phosphatidylethanol-
amine [50–52], or only one of the several enzymes
(FAAH, MAGLs, COX-2) that have been suggested to cat-
alyze 2-AG hydrolysis [10, 53], might not be sufficient to
manipulate anandamide or 2-AG tissue levels, respec-
tively; and (2) the observation that endocannabinoids, as
with other bioactive lipids, are part of a sequence of enzy-
matic reactions leading to a corresponding sequence of
chemical signals with distinct molecular targets and bio-
logical outputs. 2-AG, for example, is at the same time
the product of a family of fundamental intracellular signals,
the diacylglycerols, and the precursor of prostaglandin
glycerol esters (via COX-2), suggested to act at noncanna-
binoid receptors [54], or of arachidonic acid (via MAGL),
the progenitor of a plethora of mediators and an intracel-
lular mediator itself. Thus, the blockade of DAGLs might
not only reduce endocannabinoid signaling, but also
may enhance protein kinase C-mediated signals, whereas
inhibition of MAGLmight lead to the accumulation of pros-
taglandin glycerol esters. Although it is likely that cellular
and subcellular compartmentalization intervenes to seg-
regate these potentially concurring pathways, and per-
haps also to ensure that only one pathway contributes to
the formation or inactivation of anandamide and 2-AG
acting at cannabinoid receptors in a certain cell or tissue
(Figure 3), much work remains to validate the efficacy
and selectivity in vivo of inhibitors of endocannabinoid
metabolism.Chemistry & BioRecent data have suggested, however, that some
widely used pharmaceuticals might owe some of their
therapeutic actions to the interaction with endocannabi-
noid-biosynthesizing or -inactivating proteins. In particu-
lar, some nonsteroidal anti-inflammatory drugs (NSAIDs)
(Figure 4) possess this property. Indomethacin exerts
anti-inflammatory actions that are partly antagonized by
a CB2 receptor antagonist [55], whereas ibuprofen
enhances the analgesic actions of anandamide in a way
sensitive to both CB1 and CB2 antagonists [56], and flurbi-
profen inhibits the spinal release of proalgesic peptides in
a way that is antagonized by a CB1 antagonist [57]. Rofe-
coxib, a COX-2 inhibitor, synergizes with anandamide
while elevating the tissue levels of anandamide and other
analgesic fatty acid ethanolamides [58]. Indeed, one pos-
sible way to explain these findings is by suggesting that
these NSAIDs also inhibit FAAH, as already shown by
Fowler and collaborators for ibuprofen in 1997 [59].
More recently, the same group extended this property to
other acidic NSAIDs, and they showed that it becomes
more important when the extracellular pH is lower than
7, as during inflammatory conditions [60]. Meanwhile,
other indomethacin derivatives, such as indomethacin
methyl ester and indomethacin morpholinylamides (Fig-
ure 4), were also found to directly activate CB1 and CB2
receptors, respectively [61, 62]. More intriguingly, a recent
study [63] showed that, in rats and mice, acetaminophen
(paracetamol) is converted in vivo into p-aminophenol
and thenN-arachidonoyl-phenolamine (AM404) (Figure 4),
a compound capable of inhibiting both FAAH and ananda-
mide cellular reuptake and elevating anandamide tissue
levels [64, 65]. The second reaction is catalyzed by
FAAH (an enzyme that, under certain conditions, can facil-
itate the condensation of fatty acids with amines), thus
opening the possibility that it might also occur with other
aromatic amines used in the clinic and lead to aromatic
amides capable of interacting with other proteins of the
endocannabinoid system. Importantly, the analgesia on
a hot plate of acetaminophen is blocked by CB1 receptor
antagonists, thus confirming that this widely used drug
does also act through enhancement of the endocannabi-
noid system [66].
NSAIDs are not the only therapeutic drugs capable of
interacting with endocannabinoid enzymes. The general
anesthetic propofol (Figure 4) also inhibits FAAH, and
a part of its sedating properties is due to the subsequent
elevation of the brain levels of anandamide, which, via
CB1 receptors, can induce sleep [67]. More recently, the
antiobesity drug tetrahydrolipstatin (orlistat) (Figure 4)
was shown to inhibit DAGL-a and -b and, hence, to reduce
2-AG levels in intact cells, at concentrations lower than
those necessary to inhibit other lipases [16, 48]. Although
this compound inhibits obesity mostly by acting at the
level of lipid assimilation, it is tempting to speculate thatAbbreviations: Abh4, a/b-hydrolase 4; CB1, CB2, cannabinoid receptors of type 1 and 2, respectively; COX-2, cycloxygenase-2; FAAH, fatty acid
amide hydrolase; GPCR, G protein-coupled receptor; LPA, lysophosphatidic acid; lyso-PLD, lyso-phospholipase D;MAGL, monoacylglycerol lipase;
PKC, protein kinase C; sPLA2, secretory phospholipase A2, PLC, phospholipase C; PGE2, prostaglandin E2; PTPN22, protein tyrosine phosphatase
N22; TRPM8, transient receptor potential melastatin type 8 channel; TRPV1, transient receptor potential vanilloid type 1 channel.logy 14, July 2007 ª2007 Elsevier Ltd All rights reserved 745
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Used Therapeutic Drugs that Have Been
Reported to Interact with Proteins of the
Endocannabnoid System
The cycloxygenase inhibitor indomethacin,
and some of its derivatives, were suggested
to directly bind to and activate CB1 and/or
CB2 receptors [61, 62]. Despite the lack of
chemical similarity with anandamide, the
NSAIDs, rofecoxib, ibuprofen, and flurbipro-
fen, and the general anesthetic propofol were
suggested to act, in part, by inhibiting FAAH-
catalyzed anandamide degradation [56–60,
67]. The NSAID acetaminophen, instead, was
shown to act, in part, through the conversion
into AM404 and subsequent indirect activation
of cannabinoid receptors [63, 66]. The antiobe-
sity drug orlistat (tetrahydrolipstatin) was
shown to potently inhibit the biosynthesis of
2-arachidonoylglycerol [16, 48].part of its actions are due to inhibition of 2-AG-induced,
and CB1-mediated, gastrointestinal actions [68]. In sum-
mary, from these data the intriguing possibility emerges
that we might already be using in the clinic, without know-
ing it, substances that act in part by manipulating endo-
cannabinoid levels.
Back to Plants: Are Endocannabinoids Like
Chili Peppers?
The chemical structure of anandamide is not so different
from that of capsaicin (Figure 5A), the pungent fatty acid
amide component of another plant with a long history of
medicinal and nutritional use, the hot chili pepper Capsi-
cum annuum. In fact, capsaicin is even more chemically
similar to the aforementioned AM404 (Figure 4), which
inhibits anandamide degradation [64, 65]. After the identi-
fication by Caterina and colleagues [69] of the transient
receptor potential vanilloid-type 1 channel (TRPV1, origi-
nally known as vanilloid VR1 receptor) as the molecular
target of capsaicin (Figures 5B and 5C), we and others,
based on these chemical considerations, began to inves-
tigate the possibility that this receptor and proteins of the
endocannabinoid system share common ligands [70].
Compounds were synthesized that bind to CB1 receptors,
FAAH, or the putative anandamide membrane transporter746 Chemistry & Biology 14, July 2007 ª2007 Elsevier Ltd All rig(Figure S1), on the one hand, and to TRPV1, on the other
hand [71, 72]. More importantly, it was possible to demon-
strate that anandamide activates TRPV1 receptors [73,
74]. Later, other long-chain fatty acid ethanolamides,
i.e., the naturally occurring homologs of anandamide
(Figure 5A), and AM404 itself, were found to stimulate
the activity of TRPV1 receptors [72, 75–78], and to share
this property with other derivatives of arachidonic acid
[79]. Molecular-modeling techniques were used to dem-
onstrate that the preferential conformations of these
compounds in solution overlap with those of capsaicin
[78, 79] (Figure 5D). However, none of these endogenous
compounds appeared to be nearly as potent as capsaicin
at inducing TRPV1-mediated biological responses.
Although we now know that the ‘‘vanilloid’’ activity of
these compounds is dramatically increased by several
regulatory factors [80], this observation, together with
the original belief that vanilloid TRPV1 receptors, by being
mostly expressed in sensory afferents, are used as recep-
tors only for external painful stimuli (high temperature, low
pH, plant toxins), seemed to rule out the existence of true
‘‘endovanilloids.’’
Meanwhile, however, increasing and conclusive evi-
dence was obtained for the presence of TRPV1 receptors
in the brain [81–83], where these proteins are unlikely to behts reserved
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(A) Chemical structures ofN-acyldopamines and oleoylethanolamide, identified after the discovery of endocannabinoids and of the receptors for cap-
saicin and resiniferatoxin, the transient receptor potential vanilloid type 1 (TRPV1) channel.
(B) Three-dimensional representation of a TRPV1 monomer with the binding site for capsaicin according to Jordt and Julius [129]. According to this
model, aromatic stacking of the vanillyl moiety of capsaicin (as well as anandamide) with Tyr511 in the intracellular T2-T3 linker region stabilizes the
binding of the aliphatic chain with a transmembrane site created by the T3 and T4 domains. The observation that the T2-T3 linker domain plays a cru-
cial role in ligand recognition in both TRPV1 receptor and thementhol and ‘‘cold’’-receptor, TRPM8, led to the identification of anandamide and NADA
as TRPM8 antagonists [127].
(C) Model proposed by Gavva and colleagues according to which capsaicin, anandamide, and N-arachidonoyldopamine (NADA) bind to Tyr511
through hydrophobic binding with their aliphatic chain, whereas residues Trp549 and Thr550 are involved in binding with the vanillyl or cathecolamine
moieties of capsaicin and NADA, respectively [130].
(D) Overlap of capsaicin and oleoylethanolamide conformations in solution, according to the molecular model proposed by Movahed et al. [78].reached by exogenous stimuli, thus strongly suggesting
the existence of endovanilloid ligands [84]. Considerations
on the structure-activity relationships of synthetic vanilloid
TRPV1 agonists, which indicated the necessity of (1)Chemistry & Bia long, unsaturated alkyl chain, (2) a secondary amide
group, and (3) 3-hydroxy-4-methoxy substituents on the
aromatic moiety, in order to achieve optimal interaction
with the receptors [85, 86] (Figure 5C), together with theology 14, July 2007 ª2007 Elsevier Ltd All rights reserved 747
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ReviewTable 1. Five Families of Fatty Acid Amides
Potential Combinations
(and Compounds
Identified So Far)
Possible Target(s)
with a Known
Molecular Structure FAAH Substrate Biosynthesis
General Structure
R1
16 (12) CB1, CB2 (C20:4 > 20:3
> C22:4 > C18:3) [131];
TRPV1 (C20:4 > C18:2
> C18;1) [73, 74, 77];
TRPM8 (C20:4, which
inhibits) [127];
PPARg (C20:4) [132];
PPARa (C18:1 > C16:0)
[103]; GPR55 (C16:0,
C20:4) [107]; GPR119
(C18:1) [106]
Yes [35] Same as anandamide
(see Figure 3 and
Figure S1) [50]
16 (4) CB1 (C20:4) [87]; TRPV1
(C20:4 = C18:1) [88, 89];
TRPM8 (C20:4, which
inhibits) [127]
No. Inactivated
by COMT [88]
Condensation between
dopamine and fatty
acids [88]?
336 (44) GPR18 (R3 = Gly) [106]
(unknown for other
members)
Yes
(but not with all amino
acids) [93]
Condensation between
amino acids and fatty
acids [91]?
16 (9) TRPV1
(all of those tested)
[104]; TRPV4
(all of those tested)
[104]
Yes [97] Condensation between
taurine and acylCoAs
[104]
H 16 (5) Several proteins
(but only at micromolar
concentrations)
Yes [35] Studied only
for C18:1 [133, 134]
The possible combinations of amino acids or biogenic amines and the most abundant fatty acids found in mammalian tissues yield
newpotential endogenousmediators: theN-acyl-ethanolamines,N-acyl-dopamines,N-acyl-amino acids, andN-acyl-taurines [97–
100]. Fatty acid primary amides have also been identified [135, 136]. The targets and metabolism of only a few of the several hun-
dred possible compounds have been determined to date [103–107] and are summarized here. R2 = C12:0, C14:0, C16:0, C18:0,
C18:1, C18:2, C18:3, C20:0, C20:3, C20:4, C22:0, C22:4, C22:5, C22:6, C24:0, C24:1 alkyl chains; R3 = residues of amino acids
or GABA. COMT, catecholamine-O-methyl-transferase; FAAH, fatty acid amide hydrolase; PPAR, peroxisome-proliferator-acti-
vated receptor; TRPV, transient receptor potential vanilloid-type.realization that these prerequisites could be met, to some
extent, only by putative endogenous amides of dopamine
with long, unsaturated fatty acids, led first to the
synthesis [87] and then the isolation from the brain of
N-arachidonoyl- and N-oleoyl-dopamine [88, 89]. These
compounds (Figure 5A; Table 1) are the most potent and
efficacious endovanilloids identified to date and are most
abundant in brain regions rich in dopamine, in agreement748 Chemistry & Biology 14, July 2007 ª2007 Elsevier Ltd All rwith their potential role as endogenous TRPV1 activators
andwith their possible biosynthetic origin from theN-acyl-
ation of dopamine. They are accompanied by saturated
homologs that, although inactive per se on TRPV1, are
capable of enhancing the activity of other endovanilloids
[90]. Thus, once again, themeeting of chemical andbiolog-
icalminds led to the finding of endogenous counterparts of
a plant natural product. The importance of the discovery ofights reserved
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ReviewN-acyl-dopamines, however, went beyond that of finding
potent endogenous ligands for TRPV1 receptors, since it
supported the hypothesis that animal tissues might
make, and use as chemical signals, any combination
between fatty acids and biogenic amines.
Bioactive Fatty Acid Amides: When Animal Cells
Play Combinatorial Chemistry
That cells could ‘‘combine’’ different fatty acids and bio-
genic amines to make several possible permutations of
different fatty acid amides had been deduced already
from the discovery in rodents of N-acyl-amino acids
such as N-arachidonoyl-glycine (NAGly) and N-arachido-
noyl-alanine (Table 1), which share with fatty acid ethano-
lamides like anandamide a potent analgesic and anti-
inflammatory activity and the property of being recognized
by FAAH as substrates [91–93]. This finding raised the
possibility that any long-chain fatty acid available in tis-
sues could be amidated with any of the 20 amino acids
and their naturally occurring derivatives. This would lead
to the origination of hundreds of potential endogenous
mediators with functions and molecular targets to be dis-
covered. This possibility seems to be confirmed by the re-
cent identification of N-arachidonoyl-serine, a brain con-
stituent with vasodilatory and anti-inflammatory activity
[94], and by increasing evidence for the presence in rodent
tissues of 40 other postulated fatty acyl amides [95, 96].
How is chemical-biological research going to cope with
this ‘‘invasion’’ of new small-molecule mediators? How to
discover and measure their levels in tissues, reveal their
metabolic pathways, understand their physiological and
pathological roles and, most importantly, identify their
molecular targets? Clearly, the employment of the most
modern ‘‘omic’’ approaches for gene, protein, andmetab-
olite profiling will be required to find a function and a
‘‘parent receptor’’ to these orphan mediators, as well as
to guide their discovery. Some progress in this direction
has already been made. For example, based on the as-
sumption that at least some of these compounds would
be FAAH substrates, Cravatt and collaborators used an
original global metabolite-profiling strategy, consisting of
comparing, by the use of liquid chromatography-electro-
spray-mass spectrometric (LC-ESI-MS) techniques, the
lipid components of tissues from wild-type and FAAH
null mice, to identify new fatty amides. This led to the iden-
tification of N-acyl-taurines (Table 1) as new endogenous
amides whose levels are controlled by this enzyme [97,
98]. A similar approach, using FAAH null mice treated
with anandamide, led to the identification of a potential al-
ternative pathway for the inactivation of this compound
and other acylethanolamides through the formation of
the corresponding O-phosphorylcholine derivatives [99].
Other comparisons between lipid profiles, for example
those of distinct brain areas from mice at different phases
of their estrous cycle [100], can be used to understand the
function of the analytes. Multidimensional (tandem) mass
spectrometric techniques applied to other types of lipido-
mic-like approaches [101, 102] also seem to be very
promising for the discovery of even trace quantities of fattyChemistry & Bacid amides belonging to several families, or for the anal-
ysis of already discovered compounds [95, 100]. Thanks
to the use of ‘‘common fragment’’ methods, all of the nat-
urally occurring members of the same family of fatty acid
amides with different acyl chains but yielding common
fragments after MS-MS (Table 1) can be analyzed in the
same run (see Figure S2). Furthermore, the use of the
optimal chromatographic conditions and of LC-ESI-MS-
MS allows for the analysis of several fatty acid amide clas-
ses at the same time.
Progress is also being made in the identification of
receptors for bioactive fatty acid amides. Some serendip-
itous but nevertheless important discoveries, i.e., that
oleoylethanolamide binds to and activates peroxisome
proliferator-activated receptor a [103], or thatN-arachido-
noyl-serine activates an as-yet-unidentified endothelial
cannabinoid receptor [94], were prompted by the pharma-
cological actions observed for these compounds. N-acyl-
taurines, like acylethanolamides and acyldopamines, acti-
vate TRPV1 receptors, but they also gate a related plasma
membrane cation channel, the TRPV4 receptor [104].
Also, the finding of two GPCRs, GPR119 and GPR18, as
high-affinity receptors for oleoylethanolamide and NAGly,
respectively [105, 106], was the result of targeted
approaches. The implications of industrial patents claim-
ing that GPR55might be a high-affinity target for palmitoy-
lethanolamide have also been recently discussed [107].
However, in view of the observation that bioactive fatty
acid amides can be promiscuous in their targets, and
that the latter, as with other lipid mediators, encompass
all types of receptors (i.e., GPCRs, nuclear receptors,
ion channels [Figure 3]), it can be foreseen that more
systematic approaches, such as the use of biospecific
interaction analysis (BIAcore), protein or mRNA arrays,
and even of virtual screening methodologies, will have to
be used in the future for the ‘‘deorphanization’’ of these
novel compounds and, at the same time, of the 150 G
protein-coupled and 24 nuclear ‘‘orphan’’ receptors still
awaiting assignment of endogenous ligands. These tech-
niques, together with the MS methods mentioned above,
will have to be applied to also investigate if other amides of
fatty acids, for example with serotonin, histamine, adren-
aline, and noradrenaline, as well as with trace amines,
occur in mammalian tissues. Some of these compounds
(e.g., N-arachidonoyl-serotonin, Figure 6) have already
been synthesized and exhibit interesting pharmacological
properties (see below).
Think Like a Tinker: Making Endocannabinoid-
Based Drugs with Nature’s Bits and Pieces
If nature can combine chemical moieties to make small,
multitarget chemical signals via dedicated metabolic
pathways, the synthetic chemist can also put together
naturally occurring building blocks to make drugs that
can interact with multiple receptor types, thus obtaining,
in theory, more efficacious and therapeutically useful
pharmacological tools. Given the overlap between the
potential clinical applications (pain, inflammation, eme-
sis, cancer, etc.) and binding recognition properties ofiology 14, July 2007 ª2007 Elsevier Ltd All rights reserved 749
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Building Blocks
Combining the vanillyl moiety typical of several
plant natural products with arachidonic acid or
ricinoleic acid, and the further modification of
the chemical structures, yields compounds
with mixed activity at cannabinoid and vanilloid
TRPV1 receptors, i.e., arvanil, O-1861, and
phenyl-acetyl-ricinoleoyl-cyclopropylamide
[71, 108, 109]. The synthetic N-arachidonoyl-
serotonin mimics Nature’s capability to make
amides between long-chain fatty acids and
biogenic amines, and turned out to be a selec-
tive inhibitor of fatty acid amide hydrolase
(Table S2) and a potent antagonist at TRPV1
channels [38, 110]. Iodination of the vanillyl
moiety of a natural compound like resinifera-
toxin (RTX), or of synthetic natural product
derivatives, such as the acetylvanillyl ester of
resiniferol orthophenylacetate (ROPA) and
nor-dihydrocapsaicin, can produce opposing
effects on the activity at TRPV1 channels
[111–114]. The combination of a natural prod-
uct like olivetol and a long-chain fatty acid
yielded CB-25, a potent cannabinoid receptor
ligand with ‘‘protean’’ agonist activity in vitro
and in vivo [115–117]. Isobutyl analogs of
anandamide are more potent than the parent
compound at cannabinoid receptors, and this
is perhaps the reason why the Echinacea com-
ponents dodeca-2E,4E,8Z,10Z-tetraenoic
acid- and dodeca-2E,4E-dienoic acid-isobuty-
lamide are the only plant natural products apart
from cannabinoids that activate cannabinoid
CB2 receptors quite potently [118–121].proteins of the endocannabinoid system and TRPV1
channels, one strategy to develop hybrid therapeutic
drugs was to put together fatty acids and the vanillyl
moiety of capsaicin, each opportunely modified in order
to maximize the interaction of the end product with each
postulated target. N-arachidonoyl-vanyllamide (arvanil)
and its analog, O-1861 (Figure 6), were synthesized
with this idea in mind, and they proved to be capable
of potently activating TRPV1 receptors while acting as
agonists at CB1 receptors and inhibitors of the cellular
reuptake of anandamide [71, 108]. Both compounds
turned out to be more potent and efficacious analgesics
than pure cannabinoid or vanilloid receptor agonists
with comparable affinities for their respective receptors.
The derivatization of the hydroxy group of ricinoleic
acid, followed by amidation with chemically modified
ethylamine ‘‘heads,’’ yielded compounds with antago-750 Chemistry & Biology 14, July 2007 ª2007 Elsevier Ltd All rnist/inverse agonist activity at CB2 receptors and ago-
nist activity at TRPV1 receptors and, hence, potential
application against inflammation [109]. The aforemen-
tioned N-arachidonoyl-serotonin not only inhibits
FAAH, thus elevating endocannabinoid levels and acting
as an indirect cannabinoid receptor agonist [110], but it
is also a potent TRPV1 antagonist in vitro and in vivo,
thus exhibiting equivalent activity against neuropathic
pain as other compounds that are more potent at
FAAH [38].
However, tinkering with natural products can also lead
to unexpected results. For example, 50-iodination of resin-
iferatoxin on its vanillyl moiety (Figure 6) transforms the
ultrapotent agonist activity at TRPV1 channels of this plant
toxin into the capability to antagonize these receptors,
whereas 60-iodination only weakens its agonist activity
[111]. By converse, 60-, rather than 50-, iodination of theights reserved
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analog of capsaicin) and of other vanillamide TRPV1
ligands is required to transform their agonist activity into
potent TRPV1 antagonists [112], without decreasing the
capability of some of these compounds to directly inhibit
NF-kB activity, thus yielding dual target anti-inflammatory
and proapoptotic agents [113]. Even more intriguingly,
50-iodination of the acetylvanillyl ester of resiniferol ortho-
phenylacetate, a resiniferatoxin analog (Figure 6), yields
a compound that, instead of behaving as an antagonist
(as in the case of 50-I-resiniferatoxin) or of losing activity
(as in the case of 60-I-resiniferatoxin), is 5-fold more potent
as an agonist than the noniodinated analog [114]. On the
‘‘cannabinoid side,’’ attaching a C-11 alkylamide ‘‘head’’
to olivetol, a plant-derived compound, led to compounds
that, despite their limited conformational freedom com-
pared to endocannabinoids, bind with higher affinity to
both CB1 and CB2 receptors [115]. In this case, the sur-
prise came from the dramatically different behavior of
one these compounds (CB-25, Figure 6) in vitro and in
vivo, where it can act as a CB1 partial agonist and CB2
‘‘silent’’ antagonist or as a CB1 antagonist, respectively
[116], thus belonging to the ever growing family of recep-
tor ‘‘protean agonists’’ (i.e., compounds that can exhibit
agonist, antagonist, or inverse agonist activities depend-
ing on the constitutive ‘‘tone’’ of their receptors [117]).
If man can imitate nature by making hybrid drugs,
Nature can also imitate the human body by making endo-
cannabinoid-like natural products that potently bind to
cannabinoid receptors. This is the case for the alkylisobu-
tylamides from the roots of Echinacea angustifolia
[118–120]. These compounds, and in particular dodeca-
2E,4E,8Z,10Z-tetraenoic acid- and dodeca-2E,4E-di-
enoic acid-isobutylamide (Figure 6), bind to CB2 receptors
with higher affinity than endocannabinoids, although this
property explains only part of their strong immunomodula-
tory and anti-inflammatory properties [121]. The crosstalk
between man and Nature extends even further since C18:1
and C18:2 fatty acid ethanolamides and their correspond-
ing phospholipid precursors are also found in higher plant
seeds and leaves [122, 123], in which a functional homo-
log of the mammalian FAAH has been cloned [124]. These
anandamide congeners are inactive at cannabinoid re-
ceptors but play a role in the control of plant growth via un-
identified molecular targets [124, 125]. These chemical,
but not necessarily functional, similarities between plant
metabolites and mammalian mediators underscore the
global importance of certain metabolic pathways in eu-
karyotes, and they emphasize how cells from phylogenet-
ically distant species can exploit similar building blocks
and anabolic/catabolic strategies to respond to different
biological demands.
Take Home Messages and Open Questions
From the data reviewed in this article it is clear that biolog-
ical and pharmacological studies carried out with a chem-
ical mind can reveal new physiological and pathological
mechanisms and, eventually, solve clinical problems.
The exciting walk from the psychotropic constituent ofChemistry & BCannabis to the understanding of the mechanism of its
biological actions led to the discovery of the endocanna-
binoid system, a signaling apparatus whose function
goes well beyond what could have been imagined from
pharmacological studies on THC. The route from the
endocannabinoids to the Capsicum pungent principle
then led to the finding of endovanilloids, endogenous
mediators whose role is yet to be fully understood. The
discovery of endocannabinoids and endovanilloids paved
the way for the finding of several other lipid signals, and it
prompted, on the one hand, new strategies for the chem-
ical synthesis of compounds with multiple pharmacologi-
cal and therapeutic targets, and, on the other hand, the
search for chemically similar compounds back in plants.
Many open questions to which the meeting of chemistry
and biology can provide an answer still remain. Just to
name a few, these questions involve the understanding
of the mechanisms and exact physiological meaning of
the target and metabolic pathway promiscuity of fatty
acid ethanolamides; the identification of the elusive pro-
tein(s) facilitating endocannabinoid membrane transport;
the receptor ‘‘deorphanization’’ of the several tens of bio-
active fatty acid amides that have been discovered, and
their testing on the several TRP channels that have been
identified so far, many of which are, like TRPV1, activated
by plant natural products; the determination of the exact
function andmolecular targets of fatty acid ethanolamides
in plants; and the understanding of the mechanism of
action in animals of other phytocannabinoids, like the ther-
apeutically promising cannabidiol. Thus, the exciting
promenade from plant natural products to animal physiol-
ogy and back might soon become a true treasure hunt.
Supplemental Data
Supplemental Data include two tables and two figures, with relative
references, on the physiological and pathological functions of the en-
docannabinoid system, the mechanism of endocannabinoid retro-
grade signaling, the chemical structures and selectivity profiles of
FAAH inhibitors, and the metabolomic profiling of bioactive fatty acid
amides by spectrometric techniques and are available at http://
www.chembiol.com/cgi/content/full/14/7/741/DC1/.
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